Recently, “The Chronic Hepatitis B Treatment Algorithm” (11) in the United States recommended that regardless of HBeAg positivity or negativity, any case with elevated ALT (>30 U/L for men and >19 U/L for women) and HBV DNA ≥2,000 IU/ml should receive antiviral therapy. This evidence concerns the gene GPT and chronic hepatitis B virus infection.